Moderna, Inc. Increase (Decrease) in Contract with Customer, Liability
Moderna, Inc. (MRNA) reported Increase (Decrease) in Contract with Customer, Liability of $195.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-31
- Moderna, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $190.00M, a 95.88% increase year-over-year.
- Moderna, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $5.00M.
- Moderna, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$67.00M.
- Moderna, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $40.00M.
- Moderna, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was $41.00M.
- Moderna, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$439.00M.
- Moderna, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$2.06B.
- Moderna, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$4.16B, a 247.20% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 3 month as first filed | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 6 month as first filed | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 9 month as first filed | Increase (Decrease) in Contract with Customer, Liability 12 month | Increase (Decrease) in Contract with Customer, Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $190.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $195.00M 10-Q · filed 2026-07-31 | $128.00M derived: sum of 3 quarters · filed 2026-07-31 | $168.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $5.00M 10-Q · filed 2026-05-01 | -$62.00M derived: sum of 2 quarters · filed 2026-05-01 | -$22.00M derived: sum of 3 quarters · filed 2026-05-01 | $75.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | -$67.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$27.00M derived: sum of 2 quarters · filed 2026-02-20 | $70.00M derived: sum of 3 quarters · filed 2026-07-31 | $41.00M 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $40.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $137.00M derived: sum of 2 quarters · filed 2026-07-31 | $108.00M 10-Q · filed 2025-11-06 | -$154.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $97.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $68.00M 10-Q · filed 2026-07-31 | -$194.00M derived: sum of 3 quarters · filed 2026-07-31 | -$517.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | -$29.00M 10-Q · filed 2026-05-01 | -$291.00M derived: sum of 2 quarters · filed 2026-05-01 | -$614.00M derived: sum of 3 quarters · filed 2026-05-01 | -$435.00M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | -$262.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$585.00M derived: sum of 2 quarters · filed 2026-02-20 | -$406.00M derived: sum of 3 quarters · filed 2026-02-20 | -$439.00M 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | -$323.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$144.00M derived: sum of 2 quarters · filed 2025-11-06 | -$177.00M 10-Q · filed 2025-11-06 | -$1.06B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $179.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $146.00M 10-Q · filed 2025-08-01 | -$741.00M derived: sum of 3 quarters · filed 2026-02-20 | -$935.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | -$33.00M 10-Q · filed 2025-05-01 | -$920.00M derived: sum of 2 quarters · filed 2026-02-20 | -$1.11B derived: sum of 3 quarters · filed 2026-02-20 | -$1.27B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | -$887.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$1.08B derived: sum of 2 quarters · filed 2026-02-20 | -$1.24B derived: sum of 3 quarters · filed 2026-02-20 | -$2.06B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | -$194.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$354.00M derived: sum of 2 quarters · filed 2024-11-07 | -$1.17B 10-Q · filed 2024-11-07 | -$2.64B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | -$160.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$979.00M 10-Q · filed 2024-08-01 | -$2.44B derived: sum of 3 quarters · filed 2025-02-21 | -$2.77B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | -$819.00M 10-Q · filed 2024-05-02 | -$2.29B derived: sum of 2 quarters · filed 2025-02-21 | -$2.61B derived: sum of 3 quarters · filed 2025-02-21 | -$4.17B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | -$1.47B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$1.79B derived: sum of 2 quarters · filed 2025-02-21 | -$3.35B derived: sum of 3 quarters · filed 2025-02-21 | -$4.16B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | -$321.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$1.89B derived: sum of 2 quarters · filed 2023-11-03 | -$2.69B 10-Q · filed 2023-11-03 | -$4.30B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | -$1.56B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.37B 10-Q · filed 2023-08-03 | -$3.98B derived: sum of 3 quarters · filed 2024-02-23 | -$2.98B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | -$805.00M 10-Q · filed 2023-05-04 | -$2.41B derived: sum of 2 quarters · filed 2024-02-23 | -$1.41B derived: sum of 3 quarters · filed 2024-02-23 | -$1.65B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | -$1.61B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | -$609.00M derived: sum of 2 quarters · filed 2024-02-23 | -$842.00M derived: sum of 3 quarters · filed 2024-02-23 | $2.82B 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $998.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $765.00M derived: sum of 2 quarters · filed 2022-11-03 | $4.43B 10-Q · filed 2022-11-03 | $7.03B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | -$233.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $3.43B 10-Q · filed 2022-08-03 | $6.04B derived: sum of 3 quarters · filed 2023-02-24 | $7.22B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $3.67B 10-Q · filed 2022-05-04 | $6.27B derived: sum of 2 quarters · filed 2023-02-24 | $7.46B derived: sum of 3 quarters · filed 2023-02-24 | $7.51B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $2.60B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $3.79B derived: sum of 2 quarters · filed 2023-02-24 | $3.84B derived: sum of 3 quarters · filed 2023-02-24 | $3.84B 10-K · filed 2023-02-24 | $3.84B 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $1.19B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.24B derived: sum of 2 quarters · filed 2021-11-04 | $1.24B 10-Q · filed 2021-11-04 | $1.24B 10-Q · filed 2020-10-30 | $1.23B derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $52.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $51.00M 10-Q · filed 2021-08-05 | $51.42M 10-Q · filed 2020-08-06 | $39.80M derived: sum of 3 quarters · filed 2022-02-25 | $30.10M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | -$1.00M 10-Q · filed 2021-05-06 | -$474.00K 10-Q · filed 2020-05-07 | -$12.21M derived: sum of 2 quarters · filed 2022-02-25 | -$21.90M derived: sum of 3 quarters · filed 2022-02-25 | -$29.40M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | -$11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$20.90M derived: sum of 2 quarters · filed 2022-02-25 | -$28.40M derived: sum of 3 quarters · filed 2022-02-25 | -$44.00M 10-K · filed 2022-02-25 | -$44.12M 10-K · filed 2021-02-26 | |||
| 2019-09-30 | -$9.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | -$17.19M derived: sum of 2 quarters · filed 2020-10-30 | -$32.80M 10-Q · filed 2020-10-30 | -$60.95M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | -$7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$23.10M 10-Q · filed 2020-08-06 | -$51.26M derived: sum of 3 quarters · filed 2021-02-26 | -$86.08M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | -$15.60M 10-Q · filed 2020-05-07 | -$43.76M derived: sum of 2 quarters · filed 2021-02-26 | -$78.58M derived: sum of 3 quarters · filed 2021-02-26 | -$87.06M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | -$28.16M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$62.98M derived: sum of 2 quarters · filed 2021-02-26 | -$71.45M derived: sum of 3 quarters · filed 2021-02-26 | -$65.26M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | -$34.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$43.30M derived: sum of 2 quarters · filed 2019-11-06 | -$37.10M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | -$8.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$2.28M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $6.19M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |